Related Experiment Video
Updated: Oct 9, 2026

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
Published on: April 28, 2023
Continuous intratympanic infusion of gentamicin via a microcatheter in Menière's disease
J Schoendorf1, P Neugebauer, O Michel
1Department of Otorhinolaryngology, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50924 Cologne, Germany. jakob.schoendorf@uni-koeln.de
Abstract:
Between 1995 and 1998, 11 patients with disabling Menière's disease were treated at our institution with a continuous gentamicin infusion into the middle ear via a microcatheter. The patients had frequent attacks of vertigo and vomiting (functional levels 3-5). Hearing threshold on the affected side was significantly worse than on the healthy side (stage 4+5). Gentamicin was applied by a high-precision insulin pump with a flow rate of 40 mg per day directly in front of the round window. Application was stopped as soon as signs of vestibular affection appeared. A good overall control of vertiginous spells was achieved in 8 patients. Eight patients experienced complete hearing loss on the affected side, 1 experienced a slight worsening, and 1 had no hearing change. There was no correlation between the cumulative gentamicin dosage and the hearing loss. Our findings show that in terms of hearing loss and hospitalization time the continuous gentamicin application is inferior to other applications presented in the literature.
Insights
Continuous gentamicin infusion for Meniere's disease provided good vertigo control in 8 patients. However, this method resulted in significant hearing loss and was found to be inferior to other treatments.
Area of Science:
- Otolaryngology
- Neurosurgery
- Pharmacology
Background:
- Meniere's disease causes disabling vertigo and vomiting.
- Patients often have significant hearing loss on the affected side.
- Previous treatments for Meniere's disease have varying efficacy and side effect profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of continuous gentamicin infusion for disabling Meniere's disease.
- To assess the impact of this treatment on vertigo control and hearing function.
- To compare continuous gentamicin infusion with other treatment modalities.
Main Methods:
- 11 patients with disabling Meniere's disease received continuous gentamicin infusion via microcatheter.
- Gentamicin was delivered at 40 mg/day directly in front of the round window using an insulin pump.
- Treatment was discontinued upon signs of vestibular dysfunction.
Main Results:
- 8 out of 11 patients achieved good control of vertiginous spells.
- 8 patients experienced complete hearing loss in the affected ear; 1 had slight worsening, and 1 had no change.
- No correlation was found between cumulative gentamicin dosage and hearing loss.
Conclusions:
- Continuous gentamicin infusion can effectively control vertigo in Meniere's disease.
- This method is associated with a high incidence of hearing loss.
- Continuous infusion appears inferior to other gentamicin application methods regarding hearing preservation and hospitalization duration.
More Related Videos
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

